Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04413201
Title AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Michael Hopp
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.